Back to search results

Radiation Therapy for Ventricular Tachycardia

This study is investigating a type of radiation therapy called radioablation for people with refractory ventricular tachycardia (VT), a life-threatening heart rhythm disorder that hasn't responded to other treatments. Researchers want to see if giving radiation in a single dose is as effective and safe as giving it in three smaller doses. The study will enroll 40 participants aged 18 to 90 who have structural heart disease and severe VT. Success will be measured by how many participants have a significant reduction (60% or more) in their VT episodes, as recorded by their implantable cardioverter-defibrillator (ICD), and by tracking any serious side effects. The current recruitment status is unclear.

Study design
This is a randomized study with 40 participants. Participants will be assigned to receive either a single dose of radiation or three daily doses.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track the number of VT episodes at 6 weeks after treatment and serious side effects at 6 weeks post-treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06743789

Trial in Arrhythmia Radioablation for Ventricular Tachycardia: Single Fraction vs Three Fractions

Recruiting
NAAges 18–90InterventionalTreatment
Weill Medical College of Cornell University
~40 participants
Updated 2026-01-26 on ClinicalTrials.gov
What's tested:Radiation Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy as measured by number of subjects with a reduction ≥ 60% (tracked by ICD recordings) ventricular tachycardia (VT) episodes
Measured over 6 months before treatment
+2 more outcomes measured

Conditions

Ventricular Tachycardia

Explore related trials

Ventricular Tachycardia

NCT06743789

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Weill Cornell Medicine

    New York, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Silvia Formenti, M.D. · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University

Who to contact

Fabiana Gregucci, M.D.
[email protected]
646 962 3110
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Structural heart disease:
Refractory VT severity:
Ability to understand study protocol and to write informed consent
Willing to comply with specified pre-, post- and follow-up testing, evaluations and requirements
Expected to remain available for at least 36 months after enrollment

Exclusion

Age \< 18 years
Pregnancy
Prior chest radiation therapy

What this trial measures

  • Efficacy as measured by number of subjects with a reduction ≥ 60% (tracked by ICD recordings) ventricular tachycardia (VT) episodes6 months before treatment
  • Efficacy as measured by number of subjects with a reduction ≥ 60% (tracked by ICD recordings) ventricular tachycardia (VT) episodes6 weeks post treatment
  • Number of treatment-related serious adverse events (SAEs)6 weeks post treatment

    Safety: SAEs rate ≤ 30% defined using Common Terminology Criteria for Adverse Events (CTCAE) criteria (version 5.0) that could be treatment-related (possibly, probably, or definitely related to treatment) at 6 weeks after treatment is considered clinically acceptable. The SAEs are defined as any grade 3 toxicity requiring hospitalization or any grade 4 to 5 toxicity.